Table 2.
Clinical responses following RNA-modified dendritic cell vaccination.
| Trial Author [Ref] | Disease | CR | PR | SD | MR | PD | Total | Other Treatment | Remarks |
|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n | ||||
| Khoury [77] | AML in CR + high relapse risk | 11 (52) | - | - | - | 10 (48) | 21 | - | Sustained CRs |
| Anguille [91] | AML in CR + high relapse risk | 6 (21) | - | - | - | 22 (79) | 28 | - | Four sustained CRs |
| Wilgenhof [78] | Stage III/IV melanoma | 8 (21) | 7 (18) | 6 (15) | - | 18 (46) | 39 | Ipilimumab | - |
| Maeda [106] | HCC | 1 (8) | 1 (8) | 5 (42) | - | 5 (42) | 12 | Resection/ablation | - |
| Shindo [107] | Pancreatic cancer | 1 (2) | 3 (7) | 22 (52) | - | 16 (38) | 42 | Gemcitabine | - |
| Dannull [103] | Stage IV melanoma | 6 (50) | 1 (8) | - | - | 5 (42) | 12 | - | Five sustained CRs |
| Wilgenhof [96] | Stage III/IV melanoma | 2 (13) | 2 (13) | 4 (27) | - | 7 (47 | 15 | - | - |
| Morse [108] | CEA+ metastatic cancer MRD CEA+ metastatic cancer |
3 (25) - |
- - |
- 6 (25) |
- - |
9 (75) 18 (75) |
12 24 |
- - |
Sustained CRs - |
| Morse [109] | Pancreatic cancer | 3 (100) | - | - | - | - | 3 | 5-FU + RT, resection | Sustained CRs |
| Wilgenhof [74] | Stage III/IV melanoma | 10 (33) | - | - | - | 20 (67) | 30 | Resection +/− IFN | Sustained CRs |
| Aarntzen [90] | Stage III melanoma Stage IV melanoma |
11 (42) - |
- 1 (5) |
- 5 (23) |
- 1 (5) |
15 (58) 15 (68) |
26 22 |
- - |
Sustained CRs - |
| Kongsted [81] | Progressive metastatic CRPC | - | 1 (25) | 2 (50) | - | 1 (25) | 4 | Docetaxel | - |
| Kyte [75] | Stage IV melanoma | - | 1 (3) | 3 (10) | - | 25 (86) | 29 | +/− IL-2 | - |
| Amin [110] | mRCC | - | 9 (43) | 4 (19) | - | 8 (38) | 21 | Resection, sunitinib | - |
| Caruso [82] | Relapsed CNS tumors | - | 1 (14) | 4 (57) | - | 2 (29) | 7 | - | - |
| Borch [80] | Stage IV melanoma | - | - | 9 (41) | - | 13 (59) | 22 | CTX | - |
| Coosemans [111] | Uterine cancer | - | - | 1 (17) | 1 (17) | 4 (67) | 6 | - | - |
| Hobo [112] | Stage II/III myeloma | - | - | 5 (50) | - | 5 (50) | 10 | - | - |
| Suso [113] | Pancreatic cancer | - | - | 1 (100) | - | - | 1 | - | - |
| Markovic [84] | Stage IV melanoma | - | - | 1 (17) | - | 5 (83) | 6 | - | - |
| Mu [94] | Metastatic CRPC | - | - | 11 (58) | - | 8 (42) | 19 | - | SD based on PSA |
| Caruso [83] | Stage IV PNB | - | - | 1 (9) | - | 10 (91) | 11 | Resection, CRT | - |
| Rains [114] | Metastatic CRC | - | - | 6 (50) | - | 6 (50) | 12 | - | - |
| Sioud [115] | Stage IV melanoma | - | - | - | 1 (100) | - | 1 | Prior ipilimumab, RT | - |
| Coosemans [116] | Ovarian cancer | - | - | - | - | 2 (100) | 2 | - | - |
| Total | 62 (14) | 27 (6) | 96 (22) | 3 (0.7) | 249 (57) | 437 | |||
| CR + PR | 89 (20) | ||||||||
| CR + PR + SD | 185 (42) |
Abbreviations: 5-FU, 5-fluorouracil; AML, acute myeloid leukemia; CEA, carcinoembryonic antigen; CNS, central nervous system; CR, complete response/remission; CRC, colorectal cancer; CRT, chemoradiotherapy; CTX, cyclophosphamide; HCC, hepatocellular carcinoma; IFN, interferon; IL, interleukin; CRPC, metastatic castration-resistant prostate cancer; mRCC, metastatic renal cell carcinoma; MRD, minimal residual disease; PD, progressive disease; PNB, peripheral neuroblastoma; PR, partial response/remission; PSA, prostate-specific antigen; RT, radiotherapy; SD, stable disease.